Andrea Castro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrea Castro has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Hannah Carter
Department of Medicine, Division of Medical Genetics, University of California San Diego
38 shared publications - Maurizio Zanetti
The Laboratory of Immunology, Department of Medicine and Moores Cancer Center, University of California San Diego
36 shared publications - JungHo Kong
University of California, San Diego 2
26 shared publications - Kairi Tanaka
School of Biological Sciences, University of California San Diego, La Jolla, California
26 shared publications - Ko-Han Lee
Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, CA, USA
26 shared publications - Meghana S. Pagadala
Memorial Sloan Kettering Cancer Center, New York, NY
26 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Fig S10. A. Univariate analysis of potential checkpoint inhibitors in the discovery samples. B. Proportion of patients responding in each MHC reliance group when discovery samples are partitioned according to low versus high expression of 7 different checkpoint genes. C. Univariate analysis of potential checkpoint inhibitors in the validation samples. D. Proportion of patients responding in each MHC reliance group when validation samples are partitioned according to low versus high expression of 7 different checkpoint genes
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Fig S10. A. Univariate analysis of potential checkpoint inhibitors in the discovery samples. B. Proportion of patients responding in each MHC reliance group when discovery samples are partitioned according to low versus high expression of 7 different checkpoint genes. C. Univariate analysis of potential checkpoint inhibitors in the validation samples. D. Proportion of patients responding in each MHC reliance group when validation samples are partitioned according to low versus high expression of 7 different checkpoint genes
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Fig S6. Difference in feature importance rankings of composite model features in linear (left) versus nonlinear (right) models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Fig S6. Difference in feature importance rankings of composite model features in linear (left) versus nonlinear (right) models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Fig S8. A. MHC-I reliant patients in TCGA with melanoma, non-small cell lung cancer or renal cell carcinoma stratified by CD4/CD8 T Cell infiltration ratio. B. MHC-II reliant patients in TCGA with melanoma, non-small cell lung cancer or renal cell carcinoma stratified by CD4/CD8 T Cell infiltration ratio. P Values generated via log-rank test. C. Immune infiltrate adjusted HLA DRB1 expression is associated with prolonged survival in MHC-II Reliant TCGA patients. D. Immune infiltrate adjusted HLA DRB1 expression is not protective in MHC-I Reliant TCGA patients.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Fig S8. A. MHC-I reliant patients in TCGA with melanoma, non-small cell lung cancer or renal cell carcinoma stratified by CD4/CD8 T Cell infiltration ratio. B. MHC-II reliant patients in TCGA with melanoma, non-small cell lung cancer or renal cell carcinoma stratified by CD4/CD8 T Cell infiltration ratio. P Values generated via log-rank test. C. Immune infiltrate adjusted HLA DRB1 expression is associated with prolonged survival in MHC-II Reliant TCGA patients. D. Immune infiltrate adjusted HLA DRB1 expression is not protective in MHC-I Reliant TCGA patients.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Fig S11. A. Checkpoint expression and neoantigen levels by MHC Reliance category in discovery samples. B. Checkpoint expression and neoantigen levels by MHC Reliance category in validation samples. C. Pearson correlation between various checkpoint genes across discovery samples. D. Pearson correlation between various checkpoint genes across validation samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Fig S11. A. Checkpoint expression and neoantigen levels by MHC Reliance category in discovery samples. B. Checkpoint expression and neoantigen levels by MHC Reliance category in validation samples. C. Pearson correlation between various checkpoint genes across discovery samples. D. Pearson correlation between various checkpoint genes across validation samples.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Fig S4. A-C. Pearson correlation of three different IC-Index scores with TMB. D. Purity vs ploidy across all patients, colored by response with pearson correlation shown. E-G. ROC plots comparing the performance of composite IC-Index to TMB and clinical predictors of ICB response. H-I. ROC comparing the performance of composite IC-Index to transcriptomic predictors of ICB response J. Histogram of composite IC-Index across patients, colored by ICB response status.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Fig S4. A-C. Pearson correlation of three different IC-Index scores with TMB. D. Purity vs ploidy across all patients, colored by response with pearson correlation shown. E-G. ROC plots comparing the performance of composite IC-Index to TMB and clinical predictors of ICB response. H-I. ROC comparing the performance of composite IC-Index to transcriptomic predictors of ICB response J. Histogram of composite IC-Index across patients, colored by ICB response status.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Fig S3. A-C. SHAP derived nonlinear feature importance beeswarm plots of germline, somatic, and composite models. D-E. Correlation of immunogenicity features with TMB. F-G. Coefficients of features from linear regression-based germline and somatic models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Fig S3. A-C. SHAP derived nonlinear feature importance beeswarm plots of germline, somatic, and composite models. D-E. Correlation of immunogenicity features with TMB. F-G. Coefficients of features from linear regression-based germline and somatic models
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Fig S1. A. eQTL-score schematic. SNPs alleles are oriented so that they are all in alignment in terms of direction of effects on gene expression. Number of alleles affecting gene expression are then summed into a continuous score B. Pearson correlation of Gene level eQTL-scores in TCGA and Discovery cohorts. P<=0.05 is indicated by an X.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Fig S1. A. eQTL-score schematic. SNPs alleles are oriented so that they are all in alignment in terms of direction of effects on gene expression. Number of alleles affecting gene expression are then summed into a continuous score B. Pearson correlation of Gene level eQTL-scores in TCGA and Discovery cohorts. P<=0.05 is indicated by an X.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Fig S9. Kaplan-Meier curve of overall survival of responders only in MHC-II reliant patients vs MHC-I reliant patients for discovery group with Van Allen cohort removed.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Fig S9. Kaplan-Meier curve of overall survival of responders only in MHC-II reliant patients vs MHC-I reliant patients for discovery group with Van Allen cohort removed.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Fig S7. A. Waterfall plot of ratio of well-presented MHC-II to MHC-I neoantigens across discovery patients. B. Response rates by reliance groupings across discovery patients. Chi squared tests were performed between groups. C. MHC-I presentation pathway damage as a proportion of total number of mutations split by MHC Reliance grouping. T-tests were used to compare groups. D. Proportion of patients with any damage to MHC-I antigen presentation pathway split by MHC Reliance grouping. Chi squared tests were performed between groups. E. Immunoediting in MHC-II Reliant patients measured by SOPRANO immune dN/dS. T test was used to compare means between patients with and without MHC-I pathway damage. F. TFH cell infiltration estimates stratified by MHC-reliance grouping and ICB response. Mann-Whitney U tests were used to compare means between groups.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade
Fig S7. A. Waterfall plot of ratio of well-presented MHC-II to MHC-I neoantigens across discovery patients. B. Response rates by reliance groupings across discovery patients. Chi squared tests were performed between groups. C. MHC-I presentation pathway damage as a proportion of total number of mutations split by MHC Reliance grouping. T-tests were used to compare groups. D. Proportion of patients with any damage to MHC-I antigen presentation pathway split by MHC Reliance grouping. Chi squared tests were performed between groups. E. Immunoediting in MHC-II Reliant patients measured by SOPRANO immune dN/dS. T test was used to compare means between patients with and without MHC-I pathway damage. F. TFH cell infiltration estimates stratified by MHC-reliance grouping and ICB response. Mann-Whitney U tests were used to compare means between groups.